Diverticulitis Disease Market Report 2026

The diverticulitis disease market size has grown strongly in recent years. It will grow from $2.02 billion in 2025 to $2.21 billion in 2026 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to aging population growth, low fiber dietary habits, limited early diagnosis, hospital-centric treatment models, rising gastrointestinal disorder prevalence.

The diverticulitis disease market size is expected to see strong growth in the next few years. It will grow to $3.22 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to preventive digestive health awareness, improved imaging access, outpatient care expansion, reduced surgical intervention rates, focus on lifestyle modification. Major trends in the forecast period include increasing diagnosis of uncomplicated diverticulitis cases, rising preference for conservative and outpatient management, growing use of imaging-based diagnostic techniques, expansion of antibiotic and supportive care treatment, higher awareness of dietary and lifestyle management.

The increasing prevalence of smoking addiction is expected to drive the growth of the diverticulitis disease market in the coming years. Smoking addiction refers to a compulsive reliance on nicotine-containing products such as cigarettes, vapes, and other tobacco products. The rise in smoking addiction is attributed to factors including aggressive marketing, greater social acceptance, stress-related triggers, and the expanding availability of e-cigarettes and vaping devices. Smoking contributes to the progression of diverticular disease by reducing blood flow to the colon and increasing both the risk and severity of diverticulitis, thereby elevating the need for diagnosis and therapeutic management. For example, in October 2024, the European Respiratory Society (ERS), a Switzerland-based non-profit organization, reported findings from a study on smoking trends among young people that showed a notable increase in smoking rates, with 22.5% of respondents smoking in 2022 compared to 40.1% in 2024. Therefore, the rising prevalence of smoking addiction is fueling the growth of the diverticulitis disease market.

The growing prevalence of diabetes is also expected to propel the growth of the diverticulitis disease market. Diabetes is a chronic metabolic disorder characterized by elevated blood glucose levels resulting from impaired insulin production or utilization. Its increasing incidence is largely driven by unhealthy diets rich in processed foods, sedentary lifestyles, rising obesity rates, and aging populations. The diverticulitis disease market supports this trend by addressing diabetes-related complications, as elevated blood glucose levels weaken blood vessels and increase the colon’s susceptibility to infections and inflammation, thereby raising the demand for diagnostic and therapeutic interventions. For instance, in June 2024, the National Health Service (NHS England), a UK-based publicly funded healthcare system, reported that in 2023 the number of individuals identified with pre-diabetes rose to 3,615,330, representing an 18% increase from 3,065,825 in 2022. Among individuals under 40 years of age, cases increased by nearly 25%, from 173,166 in 2022 to 216,440 in 2023. Consequently, the increasing prevalence of diabetes is contributing to the growth of the diverticulitis disease market.

Companies operating in the diverticulitis disease market are focusing on developing and obtaining approvals for innovative drug therapies to maintain their market position. Advances in drug development are enabling the introduction of more effective treatments for diverticulitis, helping to reduce complications and improve patient outcomes. For example, in April 2023, the US Food and Drug Administration, a US-based federal agency, approved Seres’ microbiota-based drug for recurrent gastrointestinal infections. This therapy is intended to treat recurring gut infections and prevent the recurrence of Clostridioides difficile (C. diff.) infections in adults aged 18 and older. Approval of Vowst was supported by a clinical trial involving 346 patients with recurrent CDI, which demonstrated that patients receiving Vowst were significantly less likely to experience infection recurrence compared to those receiving a placebo. The oral therapy is based on microbiota containing Firmicutes spores, which help restore a healthy gut microbiome and resist C. diff. colonization.

Major companies operating in the diverticulitis disease market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Company, Cipla Limited, Hikma Pharmaceuticals PLC, Endo Pharmaceuticals, Aspen Pharmacare, Zydus Lifesciences, Lupin Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd.

North America was the largest region in the diverticulitis disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diverticulitis disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diverticulitis disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the diverticulitis disease market by increasing costs of imported diagnostic imaging equipment, antibiotics, and intravenous supplies. Hospitals in North America and Europe are most affected due to dependence on imported medical devices, while emerging regions face higher treatment costs. These tariffs increase care expenses. However, they also encourage domestic pharmaceutical production and local diagnostic infrastructure development.

The diverticulitis disease market research report is one of a series of new reports that provides diverticulitis disease market statistics, including diverticulitis disease industry global market size, regional shares, competitors with a diverticulitis disease market share, detailed diverticulitis disease market segments, market trends and opportunities, and any further data you may need to thrive in the diverticulitis disease industry. This diverticulitis disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diverticulitis disease is a medical condition marked by inflammation or infection of small pouches that form in the walls of the colon or large intestine. Common symptoms of diverticular disease include lower abdominal pain, constipation, diarrhea, and rectal bleeding.

The main types of diverticulitis disease are uncomplicated and complicated. Uncomplicated diverticulitis refers to inflammation or infection of small pouches (diverticula) that develop in the walls of the colon. Diagnostic methods include computed tomography (CT) scans, ultrasounds, urine tests, and blood tests, while treatment options include medications, surgery, supportive care, penicillin antibiotics, other antibiotics, dietary supplements, and intravenous (IV) fluids. These diagnostics and treatments are used by various end users, including specialty centers, hospitals, and research centers.

The diverticulitis disease market consists of revenues earned by entities by providing diagnostic services, pain management, nutritional therapy and follow-up services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diverticulitis disease market also includes sales of antibiotics, dietary supplements, high-fiber foods and pain medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.